ESMO Symposium on Signalling Pathways in Cancer

Daura Mella

Abstract


The 2015 Symposium will concentrate on targeting the MAPK pathway: from RAS to MEK. The programme will cover preclinical data and genetics relevant for the understanding of the functional mechanisms in the RAS/ERK/MEK pathway, regulation of MAPK signalling, the rationale and strategies to inhibiting the pathway, biomarkers, mechanisms of resistance, as well as how to overcome it, and some important interactions with other pathways.


Updates will also be provided on different aspects important for rational clinical development of novel RAS/ERK/MEK inhibitors, as well as an exploration – from a clinical perspective – of recent achievements and data from ongoing research and clinical trials, targeting the axes of the MAPK pathway across a wide range of solid tumours.

CLICK HERE for more information




Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

------------------------------------------------------------

International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.

------------------------------------------------------------

Number of visits since October, 2013
AmazingCounters.com